Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Thyroid Gland Carcinoma”

78 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 78 results

Testing effectiveness (Phase 2)Study completedNCT00537095
What this trial is testing

Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Genzyme, a Sanofi Company 164
Testing effectiveness (Phase 2)Study completedNCT00121628
What this trial is testing

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Thyroid Cancer
Amgen 184
Testing effectiveness (Phase 2)Active Not RecruitingNCT01709292
What this trial is testing

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Who this might be right for
Thyroid Cancer
M.D. Anderson Cancer Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT05989425
What this trial is testing

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Fudan University 32
Early research (Phase 1)Active Not RecruitingNCT05907304
What this trial is testing

Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Who this might be right for
Advanced or Metastatic Solid Tumors
Erasca, Inc. 86
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193186
What this trial is testing

Anlotinib and Benmelstobart in DTC

Who this might be right for
Thyroid Cancer
Fudan University 23
Testing effectiveness (Phase 2)Study completedNCT00358956
What this trial is testing

Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Genzyme, a Sanofi Company 19
Testing effectiveness (Phase 2)WithdrawnNCT02289144
What this trial is testing

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

Who this might be right for
Metastatic Anaplastic Thyroid CancerLocally Advanced Anaplastic, Undifferentiated Thyroid Cancer
University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06713057
What this trial is testing

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

Who this might be right for
Locally Advanced Thyroid Gland CarcinomaThyroid Cancer
West China Hospital 20
Not applicableActive Not RecruitingNCT03669432
What this trial is testing

To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.

Who this might be right for
Thyroid Cancer Stage IVRadiation Toxicity
Tata Memorial Hospital 72
Large-scale testing (Phase 3)Study completedNCT00410761
What this trial is testing

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Genzyme, a Sanofi Company 331
Early research (Phase 1)Study completedNCT00005647
What this trial is testing

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Who this might be right for
Head and Neck Cancer
Case Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06359847
What this trial is testing

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited 60
Testing effectiveness (Phase 2)Study completedNCT02055989
What this trial is testing

A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx

Who this might be right for
Locally Advanced Larynx, Hypopharyngeal Squamous Cell CancersLocally Advanced Thyroid Cancers
Royal Marsden NHS Foundation Trust 105
Post-approval studies (Phase 4)Not Yet RecruitingNCT07010393
What this trial is testing

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Who this might be right for
Thyroid Neoplasms
Fujian Medical University 335
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Ended earlyNCT00095693
What this trial is testing

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerInsular Thyroid CancerRecurrent Thyroid Cancer+4 more
National Cancer Institute (NCI) 25
Not applicableUnknownNCT05824312
What this trial is testing

HRQOL in Locally Advanced Thyroid Carcinoma

Who this might be right for
Thyroid CancerTyrosine Kinase InhibitorHealth Related Quality of Life
Fujian Cancer Hospital 80
Not applicableApproved For MarketingNCT01683110
What this trial is testing

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Exelixis
Load More Results